Document is current
Any future updates will be listed below
-
Authors
Zhu, Chengpei
Zhang, Chenchen
Wang, Shanshan
Xun, Ziyu
Zhang, Dongya
Lan, Zhou
Zhang, Longhao
Chao, Jiashuo
Liang, Yajun
Pu, Zilun
Ning, Cong
Sang, Xinting
Yang, Xiaobo
Wang, Hanping
Jiang, Xianzhi
Zhao, Haitao https://orcid.org/0000-0002-3444-8044
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03892577 at ClinicalTrials.govnct04010071 at ClinicalTrials.govDocuments that mention this clinical trial
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
https://doi.org/10.1136/jitc-2020-001942
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-008686
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
https://doi.org/10.1007/s00262-023-03523-2
nct03895970 at ClinicalTrials.govDocuments that mention this clinical trial
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-008686
Documents that mention this clinical trial
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
https://doi.org/10.1136/jitc-2020-001942
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-008686
-
Funding
Funding for this research was provided by:
National High Level Hospital Clinical Research Funding (2022-PUMCH-B-128)
CAMS Innovation Fund for Medical Sciences (2021-I2M-1-003)
CAMS Innovation Fund for Medical Sciences (2021-I2M-1-061)
CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-A-003)
CSCO-MSD Cancer Research Fund (Y-MSDZD2021-0213)
CSCO-hengrui Cancer Research Fund (Y-HR2019-0239)
CSCO-hengrui Cancer Research Fund (Y-HR2020MS-0415)
CSCO-hengrui Cancer Research Fund (Y-HR2020QN-0414)
National Ten-thousand Talent Program (N/A)
- License Information
